DK2696687T3 - Dobbeltacylerede GLP-1 derivater - Google Patents

Dobbeltacylerede GLP-1 derivater Download PDF

Info

Publication number
DK2696687T3
DK2696687T3 DK12713164.7T DK12713164T DK2696687T3 DK 2696687 T3 DK2696687 T3 DK 2696687T3 DK 12713164 T DK12713164 T DK 12713164T DK 2696687 T3 DK2696687 T3 DK 2696687T3
Authority
DK
Denmark
Prior art keywords
derivative
ethoxy
chem
amino
glp
Prior art date
Application number
DK12713164.7T
Other languages
English (en)
Inventor
Birgit Wieczorek
Jane Spetzler
Thomas Kruse
Lars Linderoth
Jacob Kofoed
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK2696687T3 publication Critical patent/DK2696687T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (14)

1. Derivat af en GLP-l-analog, hvorved analogen omfatter en første K-rest, svarende til position 27 i GLP-1 (7-37) (SEQ ID NO:l); en anden K-rest i en position, som svarer til position 36 i GLP-1 (7-37); og et maksimum på ti aminosyreændringer, sammenlignet med GLP-1 (7-37); hvorved den første K-rest betegnes K , og den anden K-rest betegnes K36; hvorved analogen omfatter en GLP-1 analog ifølge formel I: FORMEL I: Xaa7-Xaa8-Glu-Gly-Thr-Xaai2-Thr-Ser-Asp-Xaai8-Xaai9-Xaa2o-Glu-Xaa22-Xaa23- Xaa24-Xaa25-Arg-Lys-Phe-lle-Glu-Xaa3i-Leu-Val-Xaa34-Gly-Lys-Xaa38-Xaa39, hvorved Xaa7 er L-histidin, imidazopropionyl, α-hydroxy-histidin, D-histidin, desamino-histidin, 2-amino-histidin, β-hydroxy-histidin, homohistidin, N“-formyl-histidin, a-fluoromethyl-histidin, a-methyl-histidin, 3-pyridylalanin, 2-pyridylalanin eller 4-pyridylalanin; Xaa8 er Ala, Gly, Val, Leu, Ile, Thr, Ser, Lys, Aib, (l-aminocyclopropyl)carboxylsyre, (l-aminocyclobutyl)carboxylsyre, (l-aminocyclopentyl)carboxylsyre, (1- aminocyclohexyl)carboxylsyre, (l-aminocycloheptyl)carboxylsyre, eller (1-aminocyclooctyl)carboxylsyre; Xaan er Lys eller Phe; Xaai6 er Val eller Leu; Xaais er Ser, Arg, asn, Gin eller Glu; Xaai9 er Tyr eller Gin; Xaa2o er Leu, Lys eller Met; Xaa22 er Gly, Glu, Lys eller Aib; Xaa23 er Gin, Glu eller Arg; Xaa24 er Ala eller Lys; Xaa25 er Ala eller Val; Xaa3i er Trp eller His; Xaa34 er Glu, Asn, Gly, Gin eller Arg; Xaa37 er Gly, Ala, Glu, Pro, Lys, Arg eller mangler; Xaa3g er Ser, Gly, Ala, Glu, Gin, Pro, Arg eller mangler; og Xaa39 er Gly eller mangler; hvilket derivat omfatter to forlængende grupperinger, som er fæstnet til henholdsvis K27 og K36 via en linker, hvorved den forlængende gruppering er udvalgt blandt Chem. 2 og Chem. 1; Chem. 2: H00C-C6H4-0-(CH2)y-C0-* Chem. 1: HOOC-(CH2)x-CO-* hvorved x er et heltal i intervallet 6 - 16, og y er et heltal i intervallet 3 - 17; og linke-ren omfatter Chem. 5; Chem. 5:
hvorved h er et heltal i intervallet 1 - 5, og n er et heltal i intervallet 1-5; eller et farmaceutisk acceptabelt salt, amid eller ester deraf.
2. Derivat ifølge krav 1, hvorved Chem. 5 er inkluderet m gange, hvorved m er et heltal i intervallet 1-10.
3. Derivat ifølge et hvilket som helst af de foregående krav, hvorved k er lig med 1.
4. Derivat ifølge et hvilket som helst af de foregående krav, hvorved n er lig med 1.
5. Derivat ifølge et hvilket som helst af de foregående krav, hvorved linkeren omfatter et hvilket som helst af de foregående krav, og hvorved linkeren ydermere omfatter et Glu-radikal, som er udvalgt blandt Chem. 6, og/eller Chem. 7; Chem. 6:
og/eller Chem. 7:
6. Derivat ifølge krav 5, hvorved Glu-radikalet er inkluderet p gange, hvorved p er et heltal i intervallet 1-2.
7. Derivat ifølge et hvilket som helst af de foregående krav, hvorved linkeren er fæstnet til epsilon-aminogruppen i den første eller den anden K rest.
8. Derivat ifølge et hvilket som helst af de foregående krav, hvorved x er 12, eller hvorved Chem. 2 repræsenteres af Chem. 2b:
9. Derivat ifølge et hvilket som helst af de foregående krav, hvorved x er lig med 12, eller y er et heltal i intervallet 9-11.
10. Derivat ifølge et hvilket som helst af de foregående krav, hvorved GLP-1 analogen omfatter de følgende aminosyre-ændringer, sammenlignet med GLP-1 (7-37) (SEQ ID NO: 1): (II) 22E, 26R, 27K, 30E, 34R, 36K, 38E, 39G; (VI) 26R, 27K, 30E, 34R, 36K, 38E; (XII) 25V, 26R, 27K, 30E, 34R, 38Q; (XIII) 25V, 26R, 27K, 30E, 34Q, 36K, 38E; eller (XXVII) 8Aib, 22E, 26R, 27K, 30E, 34R, 36K, 38E, 39G; eller et farmaceutisk acceptabelt salt, amid eller ester deraf.
11. Derivat ifølge krav 10, og som omfatter et sæt aminosyre-ændringer som definereti et hvilket som helst af (II), (VI), (XII), (XIII) og (XXVII).
12. Sammensætning, udvalgt blandt følgende: N£27-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4- car- boxyphenoxy)decanoylamino]butanoyl] amino] ethoxy] ethoxy] acetyl] amino] ethoxy] ac etyl, N£36-[2-[2-[2-[[2-[2-[2-[[(4s)-4-carboxy-4-[ 10-(4- car- boxyphenoxy)decanoylamino]butanoyl] amino] ethoxy] ethoxy] acetyl] amino] ethoxy] ac etylHGlu22, Arg26, Lys27, Glu30, Arg34, Lys36]-GLP-l-(7-37)-peptidyl-Glu-Gly. Chem. 51:
Νε27 -[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[ 10-(4-car- boxyphenoxy)decanoylamino]butanoyl] amino] ethoxy] ethoxy] acetyl] amino] ethoxy] ac etyl, N£36-[2-[2-[2-[[2-[2-[2-[[(4s)-4-carboxy-4-[10-(4-carboxyphenoxy) decanoyla- mino]butanoyl] amino] ethoxy] ethoxy] acetyl] amino] ethoxy] acetyl] - [Arg26, Lys27, Glu30, Arg34, Lys36] -GLP-1-(7-37 )-peptidyl-Glu, Chem. 55:
Να(Νε27 -[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy) decanoyla-mino]butanoyl] amino] ethoxy] ethoxy] acetyl] amino] ethoxy] acetyl, Νε36- [2- [2- [2- [[2-[2-[2-[[(4s)-4-carboxy-4-[10-(4-carboxyphenoxy) decanoylamino] buta- 26 27 30 noyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]acetyl]-[Val , Arg , Lys , Glu , Arg34, Lys36]-GLP-l-(7-37)-peptidyl)-Gln, Chem. 61:
Νε27 - [2- [2- [2- [[2- [2-[2- [[(4S)-4-carboxy-4- [ 10- (4-carboxyphenoxy) decanoylami-no]butanoyl] amino] ethoxy] ethoxy] acetyl] amino]ethoxy] acetyl, Νε36- [2- [2-[2- [ [2- [2-[2-[[(4s)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino] buta- 26 27 30 noyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]acetyl]-[Val , Arg , Lys , Glu , Gin34, Lys36] -GLP-1 - (7-37)-peptidyl-Glu, Chem. 62:
N£27-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoyl-amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]acetyl, Νε36-[2-[2-[2-[[2-r2-[2-[f(4s)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino] buta- o i) 2.6 97 noyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]acetyl]-[Aib ,Glu , Arg , Lys“ , Glu30, Arg34, Lys36] -GLP-1-(7-37 )-peptidyl-Glu-Gly. Chem. 80:
N£27-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[12-(4-carboxyphenoxy) decanoylami-no]butanoyl] amino] ethoxy] ethoxy] acetyl] amino]ethoxy] acetyl], Νε36- [2-[2- [2- [ [2- [2-[2-[[(4S)-4-carboxy-4-[12-(4-carboxyphenoxy)decanoyl- amino]butanoyl] amino] ethoxy] ethoxy] acetyl] amino]ethoxy] acetyl] - [Glu22, Arg26, Lys27, Glu30, Arg34, Lys36]-GLP-l-(7-37)-peptidyl-Glu-Gly, og Chem. 81:
eller et farmaceutisk acceptabelt salt, amid eller ester deraf.
13. Derivat ifølge et hvilket som helst af kravene 1-12, med henblik på anvendelse som medikament.
14. Derivat ifølge et hvilket som helst af kravene 1 til 12, med henblik på anvendelse og/eller forebyggelse af alle former for diabetes og relaterede sygdomme, såsom spiseforstyrrelser, kardiovaskulære sygdomme, gastrointestinale sygdomme, diabetiske komplikationer, kritisk sygdom og/eller polycystisk ovarie-syndrom; og/eller med henblik på forbedring af lipid-parametre, forbedring af β-celle funktion, og/eller med henblik på forsinkelse eller forebyggelse af fremadskridende diabetisk sygdom.
DK12713164.7T 2011-04-12 2012-04-12 Dobbeltacylerede GLP-1 derivater DK2696687T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11162087 2011-04-12
US201161474913P 2011-04-13 2011-04-13
PCT/EP2012/056642 WO2012140117A1 (en) 2011-04-12 2012-04-12 Double-acylated glp-1 derivatives

Publications (1)

Publication Number Publication Date
DK2696687T3 true DK2696687T3 (da) 2017-02-06

Family

ID=47008849

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12713164.7T DK2696687T3 (da) 2011-04-12 2012-04-12 Dobbeltacylerede GLP-1 derivater

Country Status (19)

Country Link
US (5) US9266940B2 (da)
EP (2) EP3225631B1 (da)
JP (2) JP6022538B2 (da)
KR (1) KR101972836B1 (da)
CN (3) CN106117343B (da)
AU (1) AU2012241894B2 (da)
BR (1) BR112013026195A2 (da)
CA (1) CA2832811A1 (da)
DK (1) DK2696687T3 (da)
ES (1) ES2612278T3 (da)
HU (1) HUE031405T2 (da)
IL (1) IL228386A (da)
MX (1) MX355361B (da)
MY (1) MY161450A (da)
PL (1) PL2696687T3 (da)
PT (1) PT2696687T (da)
RU (1) RU2602601C2 (da)
WO (1) WO2012140117A1 (da)
ZA (1) ZA201307119B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537287T3 (es) 2009-07-13 2015-06-05 Zealand Pharma A/S Análogos de glucagón acilados
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX355361B (es) * 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
MY171146A (en) 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
EP2844669B1 (en) 2012-05-03 2018-08-01 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CA2910903A1 (en) * 2013-05-02 2014-11-06 Novo Nordisk A/S Oral dosing of glp-1 compounds
KR20160021183A (ko) * 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
AU2014286234A1 (en) * 2013-07-04 2015-12-17 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
RS57632B1 (sr) 2013-10-17 2018-11-30 Zealand Pharma As Acilovani analozi glukagona
EP3066117B1 (en) 2013-11-06 2019-01-02 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CN106029087A (zh) * 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
EP3119448B1 (en) 2014-03-21 2020-04-22 University of Pittsburgh- Of the Commonwealth System of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
EP3129041B1 (en) * 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
EP3204408B1 (en) 2014-10-10 2020-05-06 Novo Nordisk A/S Stable glp-1 based glp-1/glucagon receptor co-agonists
EP3985016A1 (en) 2014-10-29 2022-04-20 Zealand Pharma A/S Gip agonist compounds and methods
CN106999602B (zh) * 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
EP3250191B1 (en) * 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
US20180263915A1 (en) * 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
EP3283507B8 (en) 2015-04-16 2019-11-13 Zealand Pharma A/S Acylated glucagon analogue
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
ES2835033T3 (es) * 2016-03-03 2021-06-21 Novo Nordisk As Derivados de GLP-1 y sus usos
EP3534962B1 (en) * 2016-11-07 2020-08-19 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
ES2957291T3 (es) 2017-03-02 2024-01-16 Univ Pittsburgh Commonwealth Sys Higher Education Hidrogel de ECM para el tratamiento de la inflamación esofágica
ES2931299T3 (es) 2017-03-02 2022-12-28 Univ Pittsburgh Commonwealth Sys Higher Education Hidrogel de matriz extracelular (ECM) y fracción soluble del mismo para su utilización en el tratamiento del cáncer
TWI797133B (zh) * 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
WO2019117274A1 (ja) * 2017-12-15 2019-06-20 中外製薬株式会社 ペプチドの製造方法、及び塩基の処理方法
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
KR20200141469A (ko) 2018-04-05 2020-12-18 썬 파마슈티칼 인더스트리스 리미티드 신규한 glp-1 유사체
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
JP7560467B2 (ja) 2019-01-24 2024-10-02 ノヴォ ノルディスク アー／エス ローラコンパクタおよびローラコンパクタを使用する乾式造粒の方法
JP2022545862A (ja) 2019-09-02 2022-11-01 ノヴォ ノルディスク アー／エス Ｇｌｐ－１ペプチドを含む錠剤を生成するためのプロセス
BR112022007721A2 (pt) 2019-11-06 2022-07-12 Novo Nordisk As Método para o tratamento da demência
WO2021089752A1 (en) 2019-11-07 2021-05-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP4085077A4 (en) * 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
AU2021208601A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
EP4142695A1 (en) 2020-04-29 2023-03-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
EP4222176A4 (en) * 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
EP4337244A1 (en) * 2022-03-25 2024-03-20 Beijing QL Biopharmaceutical Co., Ltd. Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
EP4323413A1 (en) * 2022-03-30 2024-02-21 Beijing QL Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
KR20240053545A (ko) * 2022-10-14 2024-04-24 한미약품 주식회사 신규한 glp-1 수용체 길항제 및 이를 포함하는 선천성 고인슐린증 또는 저혈당증의 예방 또는 치료용 약학적 조성물
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
WO2024136573A1 (ko) * 2022-12-23 2024-06-27 한미약품 주식회사 신규한 glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 비만의 예방 또는 치료용 약학적 조성물
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059366T3 (es) 1986-03-12 1994-11-16 American Cyanamid Co Compuestos macrolidos.
EP0441917B1 (en) 1989-07-25 1996-05-01 The Regents Of The University Of Minnesota Pokeweed antiviral protein - monoclonal antibody conjugates
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995033474A1 (fr) 1994-06-03 1995-12-14 Tsumura & Co. Composition medicinale
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
DE122009000079I2 (de) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ATE366584T1 (de) 1996-11-12 2007-08-15 Novo Nordisk As Verwendung von glp-1 peptiden
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002512175A (ja) * 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1306091A3 (en) * 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
ATE386508T1 (de) 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
EP1175443A1 (en) 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CZ306180B6 (cs) 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1461031B1 (en) 2001-11-29 2016-06-29 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
EP1478347A1 (en) 2002-02-01 2004-11-24 Pfizer Products Inc. Dry granulated formulations of azithromycin
NZ534125A (en) 2002-02-20 2006-11-30 Emisphere Tech Inc A formulation comprising a GLP-1 compound and a delivery agent
WO2004005342A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
CA2518336A1 (en) 2003-03-19 2004-11-04 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
AU2004241242A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
EP1651248B1 (en) 2003-07-11 2009-09-09 Novartis AG Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
BRPI0417684A (pt) 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
CA2564866A1 (en) 2004-05-06 2005-11-17 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
SG153039A1 (en) 2004-05-06 2009-06-29 Emisphere Tech Inc Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate
MXPA06013252A (es) 2004-05-14 2007-02-28 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
BRPI0512988A (pt) 2004-07-08 2008-04-22 Novo Nordisk As método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
JP5175553B2 (ja) 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
JP2008531059A (ja) 2005-03-04 2008-08-14 バイオレクシス ファーマシューティカル コーポレーション 改変トランスフェリン融合タンパク質
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097536A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
EP1863449A2 (en) 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
AU2006249869A1 (en) 2005-05-26 2006-11-30 Bristol-Myers Squibb Company N-terminally modified GLP-1 receptor modulators
PT2347762T (pt) 2005-08-19 2019-06-17 Amylin Pharmaceuticals Llc Exendina para o tratamento da diabetes e redução do peso corporal
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
KR101432313B1 (ko) 2005-11-17 2014-08-20 노파르티스 아게 약제학적 조성물
US20080318861A1 (en) 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
EP2526950A1 (en) 2006-04-07 2012-11-28 Merrion Research III Limited Solid oral dosage form containing an enhancer
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
RU2451029C2 (ru) * 2006-05-09 2012-05-20 Ново Нордиск А/С Производное инсулина
US20070292512A1 (en) 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
EP2040718B1 (en) 2006-06-28 2017-12-27 Emisphere Technologies, Inc. Gallium nitrate formulations
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
JO2945B1 (en) 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
WO2008039351A2 (en) 2006-09-22 2008-04-03 Novartis Ag Method of manufacturing tablets containing pharmacologically active agents
WO2008070547A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
CN101621991A (zh) 2007-03-02 2010-01-06 诺瓦提斯公司 降钙素的口服施用
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
WO2008154619A1 (en) 2007-06-12 2008-12-18 Smithkline Beecham Corporation Methods for detecting protein in plasma
AU2008296444A1 (en) 2007-08-29 2009-03-12 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
US20100261637A1 (en) * 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
AU2008318423B2 (en) 2007-11-02 2013-12-05 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
NZ591497A (en) 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
NZ592226A (en) 2008-10-15 2012-12-21 Bayer Cropscience Ag Use of dithiin tetracarboximides for treating phytopathogenic fungi for protecting plants
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
US9544734B2 (en) * 2009-11-16 2017-01-10 Nsof Connect Ltd. Integrated network based e-commerce and analysis systems and methods
EP2512518A1 (en) * 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
JP2013514976A (ja) 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
EP2565202A4 (en) 2010-04-30 2013-10-30 Sanwa Kagaku Kenkyusho Co PEPTIDE FOR IMPROVING THE IN VIVO STABILITY OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE OR ANALOGUES AND PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ANALOGUES HAVING IN VIVO STABILITY IMPROVEMENT
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX355361B (es) * 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
MY171146A (en) 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
EP4331667A3 (en) 2012-03-22 2024-05-08 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US9764003B2 (en) 2012-07-01 2017-09-19 Novo Nordisk A/S Use of long-acting GLP-1 peptides
JP6035078B2 (ja) 2012-08-07 2016-11-30 アース製薬株式会社 多足類及びダニ類の少なくとも一方に対する忌避成分が精製、濃縮されたローズマリーオイル抽出物の製造方法
CA2910903A1 (en) 2013-05-02 2014-11-06 Novo Nordisk A/S Oral dosing of glp-1 compounds
WO2016128971A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of bone fractures and defects
EP3359181A1 (en) 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물

Also Published As

Publication number Publication date
CN106117344B (zh) 2020-11-03
US20180251512A1 (en) 2018-09-06
US9527900B2 (en) 2016-12-27
US20170058014A1 (en) 2017-03-02
US10005827B2 (en) 2018-06-26
US20200079834A1 (en) 2020-03-12
CN106117343A (zh) 2016-11-16
MX2013011674A (es) 2013-11-04
ZA201307119B (en) 2014-05-28
US9266940B2 (en) 2016-02-23
IL228386A0 (en) 2013-12-31
MX355361B (es) 2018-04-17
CN106117344A (zh) 2016-11-16
CN103619175B (zh) 2016-08-17
AU2012241894B2 (en) 2015-12-03
CA2832811A1 (en) 2012-10-18
RU2602601C2 (ru) 2016-11-20
EP2696687B1 (en) 2016-10-26
US20160083447A1 (en) 2016-03-24
IL228386A (en) 2017-01-31
RU2013148921A (ru) 2015-05-20
JP2014511870A (ja) 2014-05-19
EP3225631A1 (en) 2017-10-04
HUE031405T2 (en) 2017-07-28
KR101972836B1 (ko) 2019-04-29
ES2612278T3 (es) 2017-05-16
KR20140020309A (ko) 2014-02-18
AU2012241894A1 (en) 2013-10-03
CN103619175A (zh) 2014-03-05
MY161450A (en) 2017-04-14
US20140088005A1 (en) 2014-03-27
US11117947B2 (en) 2021-09-14
JP6271672B2 (ja) 2018-01-31
JP6022538B2 (ja) 2016-11-09
PT2696687T (pt) 2017-02-02
EP2696687A1 (en) 2014-02-19
JP2017036301A (ja) 2017-02-16
EP3225631B1 (en) 2019-01-09
BR112013026195A2 (pt) 2016-11-29
CN106117343B (zh) 2020-11-03
WO2012140117A1 (en) 2012-10-18
PL2696687T3 (pl) 2017-06-30
US11034746B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
US11117947B2 (en) Double-acylated GLP-1 derivatives
US9006178B2 (en) Double-acylated GLP-1 derivatives with a linker
EP3000482B1 (en) Double-acylated glp-1 derivatives
US10000542B2 (en) Double-acylated GLP-1 derivatives
JP2014511870A5 (da)
KR102093463B1 (ko) 이중 아실화된 ｇｌｐ-1 유도체